Role of DOR-β-arrestin1-Bcl2 signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis

Abstract

This study was aimed to investigate the role of the delta-opioid receptor (DOR)-β-arrestin1-Bcl-2 signal transduction pathway in the pathogenesis of ulcerative colitis (UC) and the intervention effects of oxymatrine on UC. Forty Sprague-Dawley rats were divided into normal group, model group, oxymatrine-treated group and mesalazine-treated group (n=10 each) at random. The rat UC model was established by intra-colonic injection of trinitrobenzene sulfonic acid in the model group and two treatment groups. The rats in oxymatrine-treated group were subjected to intramuscular injection of oxymatrine [63 mg/(kg·day)] for 15 days, and those in mesalazine-treated group given mesalazine solution [0.5 g/(kg·day)] by gastric lavage for the same days. Animals in normal group and model group were administered 3 mL water by gastric lavage for 15 days. On the 16th day, after fasting for 24 h, the rats were sacrificed for the removal of colon tissues. The expression levels of DOR, β-arrestin1 and Bcl-2 were determined in colon tissues by immunohistochemistry and real-time quantitative polymerase chain reaction (RT-PCR), respectively. It was found that the expression levels of DOR, β-arrestin1 and Bcl-2 protein and mRNA were significantly increased in the model group as compared with the other groups (P<0.05). They were conspicuously decreased in both mesalazine-treated and oxymatrine-treated groups in contrast to the model group (P<0.05). No statistically significant difference was noted in these indices between mesalazine- and oxymatrinetreated groups (P>0.05). This study indicated that the DOR-β-arrestin1-Bcl-2 signal transduction pathway may participate in the pathogenesis of UC. Moreover, oxymatrine can attenuate the development of UC by regulating the DOR-β-arrestin1-Bcl-2 signal transduction pathway.

Keywords

ulcerative colitis / delta-opioid receptor / beta-arrestin1 / Bcl-2 / oxymatrine

References

[1] MonteleoneG, CaprioliF. T-cell-directed therapies in inflammatory bowel diseases. Clin Sci (Lond), 2010, 118(12): 707-715

[2] AtreyaR, NeurathMF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol, 2008, 1(3): 175-182 PMID: 19079177

[3] SturmA, de SouzaHS, FiocchiC. Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr Drug Targets, 2008, 9(5): 381-387 PMID: 18473766

[4] ItohJ, de La MotteC, StrongSA, et al. . Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn’s disease. Gut, 2001, 49(1): 35-41 PMCID: 1728348 PMID: 11413108

[5] BidereN, SuHC, LenardoMJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol, 2006, 24: 321-352 PMID: 16551252

[6] HughesP, BouilletP, StrasserA. Role of Bim and other Bcl-2 family members In autoimmune and degenerative diseases. Curr Dir Autoimmun, 2006, 9: 74-94 PMID: 16394656

[7] FanH, LiaoY, TangQ. Role of β₂-adrenoceptor-β-arrestin2-nuclear factor-κB signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis. Chin J Integr Med (Chinese), 2012, 18(7): 514-521

[8] FanH, ChenR, ShenL, et al. . Oxymatrine improves TNBS induced colitis in rats by inhibiting the expression of NF-κBp65. J Huazhong Univ Sci Technolog Med Sci, 2008, 28(4): 415-420 PMID: 18704302

[9] ZhengP, NiuFL, LiuWZ, et al. . Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodiurn-induced colitis of rats. World J Gastroenterol, 2005, 11(31): 4912-4915 PMID: 16097071

[10] MorrisGP, BeckPL, HerridgeMS, et al. . Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 1989, 96(3): 795-803 PMID: 2914642

[11] FujinoK, TakamiY, de la FuenteSG, et al. . Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis. J Gastrointest Surg, 2004, 8(7): 842-847 PMID: 15531237

[12] GonzálezR, RodríguezS, RomayC. Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Parmacol Res, 1999, 39(1): 55-59

[13] DoeringJ, BegueB, LentzeMJ, et al. . Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn’s disease. Gut, 2004, 53(11): 1632-1638 PMCID: 1774288 PMID: 15479684

[14] SturmA, LeiteAZ, DaneseS, et al. . Divergent cell cyclekinetics underlie the distinct functional capacity of mucosal T cells in Crohn’s disease and ulcerative colitis. Gut, 2004, 53(11): 1624-1631 PMCID: 1774268 PMID: 15479683

[15] PeppelenboschMP, van DeventerSJ. T cell apoptosis and inflammatory bowel disease. Gut, 2004, 53(11): 1556-1558 PMCID: 1774279 PMID: 15479669

[16] HildemanDA, ZhuY, MitchellTC, et al. . Activated T cell death in vivo mediated by proapoptotic Bcl-2 family member Bim. Immunity, 2002, 16(6): 759-767 PMID: 12121658

[17] VeisDJ, SorensonCM, ShutterJR, et al. . Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycysticki dneys, and hypopigmented hair. Cell, 1993, 75(2): 229-240 PMID: 8402909

[18] ShiY, FengY, KangJ, et al. . Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1. Nat Immunol, 2007, 8(8): 817-824 PMID: 17618287

[19] ShenoySK, LefkowitzRJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signaling. Biochem J, 2003, 375(Pt3): 503-515 PMCID: 1223736 PMID: 12959637

[20] RevankarCM, VinesCM, CiminoDF, et al. . Arrestins block G protein-coupled receptor-mediated apoptosis. J Biol Chem, 2004, 279(23): 24578-24584 PMID: 15051714

[21] FengY, HeX, YangY, et al. . Current research on opioid receptor function. Curr Drug Targets, 2012, 13(2): 230-46 PMCID: 3371376 PMID: 22204322

[22] PolO, PalacioJR, PuigMM. The expression of δ-and κ-opioid receptor is enhanced during intestinal inflammation in mice. J Pharmacol Exp Ther, 2003, 306(2): 455-462 PMID: 12724348

[23] LvJF, FanH, ShenL, et al. . Effects of oxymatrine injection on expression of cytokines and nuclear factor-κB p65 in colonic intestinal mucosa of rats with experimental colitis. World J Gastroenterol, 2008, 16(20): 896-899